Live Breaking News & Updates on துறை ஆஃப் கண்டறியும் கதிரியக்கவியல்|Page 1

Stay updated with breaking news from துறை ஆஃப் கண்டறியும் கதிரியக்கவியல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Lower dose, less toxic radiopharmaceutical produces better outcomes


 E-Mail
Neuroendocrine tumours are cancers that begin in specialised cells called neuroendocrine cells. These cells have traits similar to those of nerve cells and hormone-producing cells. Neuroendocrine tumours, while rare, can occur anywhere in the body. Most affect the cardiothoracic region, eg lungs, appendix, small intestine, pancreas as well as the rectum. There are many types of neuroendocrine tumours: some grow slowly while others develop very rapidly.
Neuroendocrine tumors are characterised by abundant production of somatostatin receptor 2, a naturally circulating hormone that is an important target for scientists studying new treatment approaches.
Peptide Receptor Radionuclide Therapy (PRRT) is the most commonly used treatment for refractive neuroendocrine cancers, delivering cancer-killing radioactive substances directly to tumour sites. This treatment provides symptomatic relief, stopping or slowing tumour growth and improving overall survival for patients ....

Shawn Chen Xiaoyuan , Molecular Targeting Technologies Inc , Journal Of Nuclear Medicine , Chinese Academy Of Medical Science , National University Hospital , Yong Loo Lin School Of Medicine , Department Of Biomedical Engineering , Drug Administration , Union Medical College Hospital , National University Of Singapore , Department Of Diagnostic Radiology , Receptor Radionuclide Therapy , Peking Union Medical College Hospital , Chinese Academy , Medical Science , Professor Shawn Chen Xiaoyuan , Diagnostic Radiology , Yong Loo Lin School , National University , Prof Chen , Biomolecular Engineering , Biomedical Engineering , Nuclear Medicine , Professor Quek Swee Tian , Molecular Targeting Technologies , Investigational New Drug ,

Molecular Imaging Determines Effectiveness of Novel Metastatic Breast Cancer Treatment


Date Time
Molecular Imaging Determines Effectiveness of Novel Metastatic Breast Cancer Treatment
Reston, VA-Molecular imaging can successfully predict response to a novel treatment for ER-positive, HER2-negative metastatic breast cancer patients who are resistant to hormonal therapy. According to research published in the February issue of The Journal of Nuclear Medicine, positron emission tomography (PET) imaging using an imaging agent called
18F-fluoroestradiol can help to determine which patients could benefit from treatments that could spare them from unnecessary chemotherapy.
Nearly two-thirds of invasive breast cancers are ER-positive, and endocrine therapy is the mainstay of treatment for these tumors because of its favorable toxicity profile and efficacy. Should cancer progress in these patients, however, salvage endocrine therapy with molecularly targeted agents or chemotherapy can help. ....

United States , Czech Republic , University Of Pennsylvania , Fred Hutchinson Cancer Research Center , Kennetha Krohn , Hannahm Linden , Alena Novakova Jiresova , Fengting Yan , Vijayakrishnak Gadi , Brendaf Kurland , Davida Mankoff , Erink Schubert , Jenniferm Specht , Julier Gralow , Journal Of Nuclear Medicine , Department Of Radiology , Public Health Sciences Division , National Cancer Institute , Oregon Health , University Of Washington Seattle Cancer Care Alliance , University Of Pittsburgh , Clinical Research , Division Of Medical Oncology , Department Of Biostatistics , Cancer Imaging Program , Department Of Diagnostic Radiology ,

New Cardiac Diagnostic Tool Helps Automate Point-of-Care Ultrasound Screening


New Cardiac Diagnostic Tool Helps Automate Point-of-Care Ultrasound Screening
New algorithmic module provides automated expert-level assessment of heart function from parasternal long axis view for point of care medical teams
A new algorithmic module from OEM ultrasound AI software vendor RSIP Vision provides automated expert-level assessment of heart function from parasternal long axis view for point of care medical teams.
January 8, 2020 – RSIP Vision has launched a new artificial intelligence (AI) ultrasound module that enables fast and accurate point-of-care heart evaluations. This includes onsite diagnostic from the parasternal long axis (PLAX) view. This new vendor-neutral technology will be available to third-party ultrasound manufacturers and medical devices vendors. ....

Tel Aviv , Ron Soferman , Sourasky Medical Center , Department Of Diagnostic Radiology , Rabeeh Fares , Diagnostic Radiology , தொலைபேசி அவிவ் , துறை ஆஃப் கண்டறியும் கதிரியக்கவியல் , கண்டறியும் கதிரியக்கவியல் ,